Kiora Pharmaceuticals Inc. [NASDAQ: KPRX] gained 17.42% or 0.02 points to close at $0.18 with a heavy trading volume of 29816987 shares. The company report on July 28, 2022 that Kiora Pharmaceuticals Issued US Patent Covering KIO-201 Technology in Combination with Antibiotics.
Top 5 Cheap Stocks to Own Right Now
While finding safe stocks with the potential for monster gains isn't always easy, we've found a few that could pay out well. In fact, within our report, "Top 5 Cheap Stock to Own Right Now", we have identified five stocks we believe could appreciate the most even if you just have $1,000 to invest.
Sign up here to get your free report now. .
Salt Lake City, Utah–(Newsfile Corp. – July 28, 2022) – Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX) (“Kiora” or the “Company”) has been granted a U.S. patent covering hydrogel-based sustained release platforms, inclusive of KIO-201, which enable controlled release of antibiotics for the treatment of ocular diseases. The intellectual property, US Patent No. 11,376,214, relates to non-blurring, antibiotic-containing hydrogel compositions that have an extended contact time on the eye and have potential to further improve the health of the ocular surface for accelerated wound healing.
“This patent strengthens our commercial position for next-generation versions for KIO-201,” said Brian M. Strem, Ph.D., President and Chief Executive Officer of Kiora. “In addition to potentially repairing corneal wounds as a standalone treatment, we see opportunities to employ our technology in combination with antibiotics to further accelerate wound healing and reduce post-surgical complications, including infections.”.
It opened the trading session at $0.16, the shares rose to $0.193 and dropped to $0.1591, the range by which the price of stock traded the whole day. The daily chart for KPRX points out that the company has recorded -75.05% loss over the past six months. However, it is still -28.57% lower than its most recent low trading price.
If we look at the average trading volume of 1.02M shares, KPRX reached to a volume of 29816987 in the most recent trading day, which is why market watchdogs consider the stock to be active.
Here is what top equities market gurus are saying about Kiora Pharmaceuticals Inc. [KPRX]:
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for KPRX shares is $7.00 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on KPRX stock is a recommendation set at 2.00. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
The Average True Range (ATR) for Kiora Pharmaceuticals Inc. is set at 0.03 The Price to Book ratio for the last quarter was 0.21, with the Price to Cash per share for the same quarter was set at 0.36.
Trading performance analysis for KPRX stock
Kiora Pharmaceuticals Inc. [KPRX] gain into the green zone at the end of the last week, gaining into a positive trend and gaining by 14.75. With this latest performance, KPRX shares dropped by -53.17% in over the last four-week period, additionally sinking by -75.05% over the last 6 months – not to mention a drop of -89.78% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for KPRX stock in for the last two-week period is set at 38.66, with the RSI for the last a single of trading hit 46.75, and the three-weeks RSI is set at 37.00 for Kiora Pharmaceuticals Inc. [KPRX]. The present Moving Average for the last 50 days of trading for this stock 0.3161, while it was recorded at 0.1586 for the last single week of trading, and 0.7427 for the last 200 days.
Kiora Pharmaceuticals Inc. [KPRX]: A deeper dive into fundamental analysis
Return on Equity for this stock declined to -127.63, with Return on Assets sitting at -78.05.
Kiora Pharmaceuticals Inc.’s liquidity data is similarly interesting compelling, with a Quick Ratio of 2.60 and a Current Ratio set at 2.60.
An analysis of insider ownership at Kiora Pharmaceuticals Inc. [KPRX]
There are presently around $0 million, or 22.70% of KPRX stock, in the hands of institutional investors. The top three institutional holders of KPRX stocks are: GEODE CAPITAL MANAGEMENT, LLC with ownership of 529,764, which is approximately 1.109% of the company’s market cap and around 0.20% of the total institutional ownership; RENAISSANCE TECHNOLOGIES LLC, holding 93,619 shares of the stock with an approximate value of $17000.0 in KPRX stocks shares; and VANGUARD GROUP INC, currently with $14000.0 in KPRX stock with ownership of nearly -49.236% of the company’s market capitalization.
Positions in Kiora Pharmaceuticals Inc. stocks held by institutional investors increased at the end of August and at the time of the August reporting period, where 9 institutional holders increased their position in Kiora Pharmaceuticals Inc. [NASDAQ:KPRX] by around 181,134 shares. Additionally, 4 investors decreased positions by around 106,943 shares, while 5 investors held positions by with 571,358 shares. The mentioned changes placed institutional holdings at 859,435 shares, according to the latest SEC report filing. KPRX stock had 4 new institutional investments in for a total of 136,024 shares, while 3 institutional investors sold positions of 32,251 shares during the same period.